Therefore, researchers can use mRNA degradation strategies and small inhibitory molecules for targeted Bcl-2 therapy in a variety of cancers, such as breast cancer, colon cancer, and prostate cancer (Li et al., 2016). The gene discussed is BCL2; the disease is cancer.